Aquestive Faces Class Action Over Anaphylm FDA Approval Misstatements

Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Aquestive Therapeutics, Inc. ($AQST), alleging the company misled investors about the likelihood of FDA approval for its flagship drug Anaphylm. The legal action centers on claims that Aquestive failed to disclose material deficiencies identified by the FDA that ultimately precluded approval by the January 31, 2026 deadline, triggering a sharp market correction. Investors who suffered losses have until May 4, 2026 to apply for lead plaintiff status in the litigation.

The FDA Setback and Stock Collapse

The controversy erupted on January 9, 2026, when Aquestive Therapeutics announced that the FDA would not approve Anaphylm by the originally targeted deadline. The revelation sent shockwaves through the market, with Aquestive's stock price plummeting 37% in a single trading session—a devastating blow for shareholders who had positioned themselves based on the company's previous disclosures regarding approval prospects.

According to the lawsuit allegations, Aquestive had material knowledge of specific deficiencies flagged by FDA reviewers but failed to adequately communicate these obstacles to investors. The timing of the disclosure raises questions about whether the company delayed communicating FDA concerns, allowing shareholders to remain in the dark about significant regulatory headwinds. This type of information asymmetry—where management possesses material non-public information about product prospects—forms the foundation of securities fraud allegations.

The Anaphylm setback represents a critical inflection point for Aquestive Therapeutics, as the company's commercial prospects and financial trajectory likely hinged substantially on obtaining FDA approval for this therapeutic candidate. For a smaller biopharmaceutical firm, a single failed approval can be existential, making the pre-announcement disclosure practices under intense scrutiny.

Market Context and Competitive Landscape

Biopharmaceutical companies routinely face FDA approval uncertainties, but investors typically expect transparent communication about regulatory feedback and approval likelihood. The sector experienced heightened regulatory scrutiny in recent years, with the FDA maintaining rigorous standards for novel therapeutics. Anaphylm, positioned as an anaphylaxis treatment, operates in a therapeutic space where efficacy and safety standards are particularly stringent given the life-threatening nature of anaphylactic reactions.

The allegations against Aquestive align with a broader pattern of securities litigation targeting pharmaceutical and biotech firms following unexpected FDA decisions. Investors have grown increasingly litigious when companies fail to transparently disclose regulatory feedback, particularly when FDA communications suggest material approval barriers. The class action mechanism serves as an important accountability tool in this context, as individual shareholders typically lack resources to pursue litigation independently against well-capitalized corporations.

For Aquestive Therapeutics specifically, the 37% stock decline reflects not merely the loss of anticipated revenues from Anaphylm, but also erosion of investor confidence in management's transparency and regulatory judgment. This credibility loss can impact future capital-raising efforts, partnerships, and shareholder relations.

Investor Implications and Lead Plaintiff Deadline

The May 4, 2026 deadline for lead plaintiff applications carries significant weight for affected shareholders. The lead plaintiff typically bears the responsibility of directing litigation strategy, approving settlements, and representing the broader class of injured investors. For shareholders with substantial losses from their Aquestive holdings during the relevant period, securing lead plaintiff status offers influence over the case's trajectory.

Key considerations for investors evaluating potential claims include:

• Timing of purchase: Shareholders who acquired Aquestive stock before the regulatory concerns became public face the strongest cases
• Holding period: Longer ownership tenures may indicate greater reliance on the company's statements about approval prospects
• Documentation: Email communications, investor presentations, and conference call transcripts constitute critical evidence regarding what management knew and when
• Damages calculation: The 37% stock price decline provides a baseline for quantifying losses, though actual recoverable damages depend on litigation outcomes

Historically, securities class actions against biopharmaceutical companies have achieved mixed results. Some settlements have recovered meaningful portions of shareholder losses, while others have yielded nominal payments relative to aggregate investor harm. The strength of Aquestive's alleged misconduct—specifically whether the company had clear FDA feedback it failed to disclose—will substantially influence case viability.

Investors should note that Bragar Eagel & Squire, P.C. is actively soliciting lead plaintiff applications, suggesting the firm believes it has identified material misrepresentation claims. However, litigation outcomes remain uncertain, and shareholders should carefully evaluate the evidence and their own factual situations before committing resources to participation.

Forward Outlook

The Aquestive Therapeutics litigation underscores the critical importance of transparent regulatory disclosure in life sciences investing. For the company itself, management must now navigate the dual challenge of addressing shareholder litigation while attempting to salvage the Anaphylm program or develop alternative pathways forward. The FDA feedback that allegedly precluded approval may or may not be remediable through additional development work, adding another layer of uncertainty.

For the broader biopharmaceutical sector, the case reinforces that FDA communications must be promptly and accurately reflected in investor disclosures. Companies that obscure, downplay, or delay communicating regulatory obstacles expose themselves to significant legal liability and reputational damage. As institutional investors increasingly focus on governance and transparency issues, securities litigation related to regulatory disclosure failures may constitute an emerging risk factor for smaller biotech firms with pipeline-dependent business models.

Shareholders with potential claims against Aquestive Therapeutics should consult with qualified legal counsel regarding their eligibility and the May 4, 2026 application deadline.